nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2015-1-61-65nodgo-80Research ArticleОригинальные исследованияПедиатрические тромбозы: применение далтепарина натрия для лечения и профилактикиPediatric thrombosis: application of dalteparin for treatment and preventionСвиринПавел ВячеславовичSvirinP. V.

Россия, 119049, Москва, 4-й Добрынинский пер., 1/9;

Россия, 117997, Москва, ул. Островитянова, 1

1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia;

1 Ostrovityanova St., Moscow, 117997, Russia

pavel_svirin@inbox.ruЛаринаЛ. Е.LarinaL. E.

Россия, 117997, Москва, ул. Островитянова, 1

1 Ostrovityanova St., Moscow, 117997, Russia

ЖарковП. А.ZharkovP. A.

Россия, 117198, Москва, ул. Саморы Машела, 1

1 Samory Mashela St., Moscow, 117198, Russia

КазанковаА. А.KazankovaA. A.

Россия, 119049, Москва, 4-й Добрынинский пер., 1/9

1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia

ПетровВ. Ю.PetrovV. Yu.

Россия, 119049, Москва, 4-й Добрынинский пер., 1/9

1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia

ЛаврентьеваИ. Н.LavrentyevaI. N.

Россия, 119049, Москва, 4-й Добрынинский пер., 1/9

1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia

ГБУЗ «Морозовская детская городская клиническая больница»; ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияMorozov Children's Hospital; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава РоссииРоссияFederal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaRussian FederationГБУЗ «Морозовская детская городская клиническая больница»РоссияMorozov Children, s HospitalRussian Federation201523052015216165Copyright © Свирин П.В., Ларина Л.Е., Жарков П.А., Казанкова А.А., Петров В.Ю., Лаврентьева И.Н., 20152015Свирин П.В., Ларина Л.Е., Жарков П.А., Казанкова А.А., Петров В.Ю., Лаврентьева И.Н.Svirin P.V., Larina L.E., Zharkov P.A., Kazankova A.A., Petrov V.Y., Lavrentyeva I.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/80

Приведен анализ результатов применения далтепарина натрия (препарата Фрагмин®) для профилактики и лечения тромбозов различной локализации у 62 детей. Оценены средние относительные дозы в зависимости от возраста пациентов, эффективность применения и безопасность препарата; необходимость индивидуального контролируемого подбора дозы.

The analysis of the results of dalteparin sodium (Fragmin®) application for the prevention and treatment of thrombosis of various biodisposition in 62 children has been given. The average relative dose depending on the age of the patient, the effectiveness of application and the drug, s safety; the need to select individually controlled doses has been evaluated.

тромбознизкомолекулярные гепариныдалтепарин натрияФрагмин®нефракционированный гепаринthrombosislow-molecular heparinsdalteparin sodiumFragmin®unfractionated heparinReferencesFisher T. Four Cases of Primary Thrombosis of Cerebral Veins and Sinuses in Children. Br Med J 1901;2(2114):9–12.Fisher T. Four Cases of Primary Thrombosis of Cerebral Veins and Sinuses in Children. Br Med J 1901;2(2114):9–12.Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74(1):415–25.Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74(1):415–25.Andrew M., Vegh P., Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992;80(8):1998–2005.Andrew M., Vegh P., Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992;80(8):1998–2005.Nowak-Gottl U., Kosch A., Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86(1):464–74.Nowak-Gottl U., Kosch A., Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86(1):464–74.Nowak-Gottl U., Kurnik K., Krumpel A., Stoll M. Thrombophilia in the young. Hamostaseologie 2008;28(1–2):16–20.Nowak-Gottl U., Kurnik K., Krumpel A., Stoll M. Thrombophilia in the young. Hamostaseologie 2008;28(1–2):16–20.Monagle P., Chan A.K., Goldenberg N.A. et al. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: e737S–e801.Monagle P., Chan A.K., Goldenberg N.A. et al. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: e737S–e801.Bidlingmaier С., Kenet G., Kurnik K. et al. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost 2011;37(7):814–25.Bidlingmaier С., Kenet G., Kurnik K. et al. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost 2011;37(7):814–25.Pineo G.F., Hull R.D. Dalteparin sodium. Expert Opin Pharmacother 2001;2(8): 1325–37.Pineo G.F., Hull R.D. Dalteparin sodium. Expert Opin Pharmacother 2001;2(8): 1325–37.Massicotte P., Adams M., Marzinotto V. et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128(3):313–8.Massicotte P., Adams M., Marzinotto V. et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128(3):313–8.Punzalan R.C., Hillery C.A., Montgomery R.R. et al. Low-molecularweight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000;22(2):137–42.Punzalan R.C., Hillery C.A., Montgomery R.R. et al. Low-molecularweight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000;22(2):137–42.Massicotte P., Julian J.A., Marzinotto V. et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003;109(2–3):93–9.Massicotte P., Julian J.A., Marzinotto V. et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003;109(2–3):93–9.Laporte S., Mismetti P., Piquet P. et al. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci 1999;8(2):119–25.Laporte S., Mismetti P., Piquet P. et al. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci 1999;8(2):119–25.Kuhle S., Massicotte P., Dinyari M. et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005;94(6):1164–71.Kuhle S., Massicotte P., Dinyari M. et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005;94(6):1164–71.Trame M.N., Mitchell L., Krumpel A. et al. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. J Thromb Haemost 2010;8(9):1950–8.Trame M.N., Mitchell L., Krumpel A. et al. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. J Thromb Haemost 2010;8(9):1950–8.O'Brien S.H., Kulkarni R., Wallace A. et al. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. J Thromb Haemost 2014;12(11):1822–5.O'Brien S.H., Kulkarni R., Wallace A. et al. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. J Thromb Haemost 2014;12(11):1822–5.Nohe N., Flemmer A., Rumler R. et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999;158(Suppl 3):134–9.Nohe N., Flemmer A., Rumler R. et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999;158(Suppl 3):134–9.Inamo Y., Saito K., Hasegawa M. et al. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study. BMC Pediatr 2014;14:27.Inamo Y., Saito K., Hasegawa M. et al. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study. BMC Pediatr 2014;14:27.Goldenberg N.A., Jacobson L., Hathaway H. et al. Anti-Xa stability of diluted dalteparin for pediatric use. Ann Pharmacother 2008;42(4):511–5.Goldenberg N.A., Jacobson L., Hathaway H. et al. Anti-Xa stability of diluted dalteparin for pediatric use. Ann Pharmacother 2008;42(4):511–5.

The authors declare that there are no conflicts of interest present.